Ketamine Treatment: How We Talk About Psychedelic Effects

‍Language That Respects Patients: How We Talk About Ketamine’s Psychedelic Effects

Words are part of the treatment. They set expectations, shape safety, and influence how people feel walking into the room. At Lumin Health, we avoid hype and center our framing around your agency. When we describe ketamine treatment — including esketamine (Spravato) — we name what we know, what we don’t, and what you can choose. Our philosophy remains that patients deserve clarity over categories.

Ketamine: Dissociative anesthetic with psychedelic effects

Medically, ketamine is a dissociative anesthetic.^[1] Experientially, many people describe psychedelic effects: altered perception, a softer grip on rigid thoughts, and a new vantage point on difficult feelings. We hold both truths on purpose.

Why it matters: Calling ketamine treatment “a trip” can trivialize risk and encourage thrill-seeking. Calling it “just anesthesia” can ignore the meaning-making that patients experience. Our phrasing invites a middle path: evidence-led medicine that takes subjective experience seriously.

Why we say esketamine (Spravato)

When we reference the nasal-spray formulation, we write esketamine (Spravato) first, then “Spravato” for short. Esketamine is the chemical name for the compound, and Spravato is the brand name given by Janssen, the manufacturer. That order keeps the science and the brand straight, and reminds everyone we’re discussing an FDA-approved option provided within a REMS-governed framework in a monitored Spravato clinic.^[2] 

• Plain-language takeaway: Off-label ketamine and esketamine (Spravato) are different programs with overlapping goals. Which one fits you depends on diagnosis, medical history, access, and logistics, which you will discuss in detail with your expert team of Lumin Health clinicians. 

Qualifiers and clinical humility in ketamine (on purpose)

We use careful qualifiers because individual responses vary notably — and because honesty is part of safety.^[3]

• We say “may help,” “in some patients,” “clinicians often see” when outcomes differ person to person.
• We describe ranges and windows, not guarantees.
• We talk openly about risks and non-response, and how we adjust dose, route, timing, and available support systems when the first plan isn’t working.

This approach isn’t intended to dilute hope. It protects it — by keeping expectations real for anyone pursuing ketamine therapy for depression.

Ketamine Therapy and Spravato at Lumin Health: Person-first communication: Person-first communication

You are not your diagnosis. We talk to you, not about you.

• Agency: You set intentions; we steward the medical details.
• Plain language: We translate terms like neuroplasticity and dissociation into lived experience.
• Supportive follow-through: We help you use the neuroplasticity window — the hours to days after dosing when new learning may land more readily — within your familiar, existing care routine.

Language that protects your safety — and your say

At Lumin Health, we’ll keep using words that do their job: protect safety, reflect the evidence, share the evidence of ketamine therapy and Spravato being potentially effective treatment options for depression, and leave room for your experience. Whether you pursue off-label ketamine treatment or esketamine in a Spravato program, you’ll hear the same tone from us — clear, careful, and hopeful without hype — so you can decide what feels possible for you.

References

1. Zanos P, Moaddel R, Morris PJ, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev. 2018;70(3):621-660. PubMed
2. Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019;176(6):428-438. PubMed
3. Price RB, Kissel N, Baumeister A, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry. 2022;27(12):5096-5112. PubMed

You've read the science. Now take the next step.

Lumin Health provides safe, expert-administered ketamine and Spravato treatment across Massachusetts and the greater Washington DC/Maryland area. Your journey starts with a free, no-commitment intro call.

Available in Massachusetts and the greater Washington DC/Maryland area.

Book a Free Intro Call

Frequently Asked Questions

Will ketamine or Spravato treatment make my depression go away completely?

Not necessarily, and Lumin Health won't promise that outcome. Depression is complex and individual, so treatment may create conditions for symptom relief and new habits rather than promise a specific result. Some people see meaningful, sustained improvement, while others need a dose change, a different route, or a different path.

What if I'm unsure about starting ketamine therapy?

Uncertainty is welcome, and Lumin Health will slow down to explore your goals, questions, and boundaries with you. Choosing ketamine therapy for depression isn't an all-or-nothing decision. It's a series of small, reversible steps taken at your pace.

Why does Lumin Health name esketamine before the brand name Spravato?

Esketamine is the chemical name, and Spravato is the brand name given by the manufacturer, so naming the chemical first keeps the science and the brand straight. It's also a reminder that this is an FDA-approved option delivered within a REMS-governed framework.

How does Lumin Health talk about ketamine's dissociative and psychedelic effects?

We hold two truths at once: medically, ketamine is a dissociative anesthetic, and experientially, many people describe psychedelic effects like altered perception or a softer grip on rigid thoughts. Calling it a trip can trivialize risk, and calling it just anesthesia can miss the meaning-making patients experience, so we aim for language that takes both seriously.